Review



anti mybl2 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech anti mybl2 antibody
    Anti Mybl2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mybl2 antibody/product/Proteintech
    Average 93 stars, based on 26 article reviews
    anti mybl2 antibody - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    94
    Sino Biological mybl2 flag
    Mybl2 Flag, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mybl2 flag/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    mybl2 flag - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    93
    Sino Biological mybl2 ha hg14536 cy plasmids 145
    Mybl2 Ha Hg14536 Cy Plasmids 145, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mybl2 ha hg14536 cy plasmids 145/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    mybl2 ha hg14536 cy plasmids 145 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    86
    Shanghai Genechem Ltd mybl2
    Mybl2, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mybl2/product/Shanghai Genechem Ltd
    Average 86 stars, based on 1 article reviews
    mybl2 - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    93
    Proteintech anti mybl2 antibody
    Anti Mybl2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mybl2 antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti mybl2 antibody - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Proteintech antibodies against mybl2
    Antibodies Against Mybl2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against mybl2/product/Proteintech
    Average 93 stars, based on 1 article reviews
    antibodies against mybl2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Proteintech mybl2 specific antibody
    Mybl2 Specific Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mybl2 specific antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    mybl2 specific antibody - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Proteintech anti mouse mybl2
    The expression of MYCN and <t>MYBL2</t> was elevated in SHH MB patients and correlates with a poor prognosis. ( A ) MYCN and MYBL2 expression levels in SHH MB tumors and normal brains (NBs) were analyzed from the TVGH/TMUH cohort. Data are represented as mean ± SD ( n = 3 for the NB group, n = 24 for the SHH group). Statistical analyses were performed using the Student’s t -test. ( B ) Correlation of MYCN and MYBL2 gene expression. ( C ) Ratio of MYCN and MYBL2 expression in SHH MB patients. ( D ) Overall survival of SHH MB patients with high or low levels of MYCN and MYBL2
    Anti Mouse Mybl2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse mybl2/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti mouse mybl2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Proteintech anti mybl2
    The expression of MYCN and <t>MYBL2</t> was elevated in SHH MB patients and correlates with a poor prognosis. ( A ) MYCN and MYBL2 expression levels in SHH MB tumors and normal brains (NBs) were analyzed from the TVGH/TMUH cohort. Data are represented as mean ± SD ( n = 3 for the NB group, n = 24 for the SHH group). Statistical analyses were performed using the Student’s t -test. ( B ) Correlation of MYCN and MYBL2 gene expression. ( C ) Ratio of MYCN and MYBL2 expression in SHH MB patients. ( D ) Overall survival of SHH MB patients with high or low levels of MYCN and MYBL2
    Anti Mybl2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mybl2/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti mybl2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    The expression of MYCN and MYBL2 was elevated in SHH MB patients and correlates with a poor prognosis. ( A ) MYCN and MYBL2 expression levels in SHH MB tumors and normal brains (NBs) were analyzed from the TVGH/TMUH cohort. Data are represented as mean ± SD ( n = 3 for the NB group, n = 24 for the SHH group). Statistical analyses were performed using the Student’s t -test. ( B ) Correlation of MYCN and MYBL2 gene expression. ( C ) Ratio of MYCN and MYBL2 expression in SHH MB patients. ( D ) Overall survival of SHH MB patients with high or low levels of MYCN and MYBL2

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: The expression of MYCN and MYBL2 was elevated in SHH MB patients and correlates with a poor prognosis. ( A ) MYCN and MYBL2 expression levels in SHH MB tumors and normal brains (NBs) were analyzed from the TVGH/TMUH cohort. Data are represented as mean ± SD ( n = 3 for the NB group, n = 24 for the SHH group). Statistical analyses were performed using the Student’s t -test. ( B ) Correlation of MYCN and MYBL2 gene expression. ( C ) Ratio of MYCN and MYBL2 expression in SHH MB patients. ( D ) Overall survival of SHH MB patients with high or low levels of MYCN and MYBL2

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Expressing, Gene Expression

    DMGF induced apoptotic cell death and cell cycle arrest through inhibiting MYCN and MYBL2 expression. ( A ) Inhibitory effects of DMGF on cell proliferation. MB cells were treated with various concentrations of DMGF for 48 h. Cell viability was measured by MTT assay. Results are shown as mean ± SD ( n = 6). ( B , C ) DMGF increased active caspase-3 activity and TUNEL signals. Paclitaxel (30 ng/mL) was used as a positive control. Ctrl: control (untreated) cells. P: Paclitaxel 30 ng/mL. D1 and D2: DMGF 1 and 2 µg/mL. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared to the control group using one-way ANOVA followed by Dunnett’s multiple comparison test. ( D ) The top 10 differentially down-regulated hallmark pathways in Daoy-MYCN cells after DMGF treatment. ( E ) The genes that overlap with the genes in the hallmark gene sets of MYC target v1, MYC target v2, and G2M checkpoint in Daoy-MYCN cells after DMGF treatment. ( F ) DMGF suppressed MYCN and MYBL2 expression in MB cells. MB cells were treated with DMGF for 48 h; MYCN and MYBL2 were detected by western blot. ( G ) Cell cycle distribution of DMGF-treated MB cells. After treatment for 24 h with DMGF (0 and 2 µg/mL), a propidium iodide staining assay was performed on MB cells. Cell cycle distribution was detected by flow cytometry. All data are represented as mean ± S.D. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared to the control group using one-way ANOVA followed by Dunnett’s multiple comparison test. ( H ) Effect of DMGF on expression of cell cycle checkpoint proteins, such as cyclins, CDKs, p21 and p27. All cell cycle checkpoint proteins were analyzed by Western blot. β-actin was used as a loading control

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: DMGF induced apoptotic cell death and cell cycle arrest through inhibiting MYCN and MYBL2 expression. ( A ) Inhibitory effects of DMGF on cell proliferation. MB cells were treated with various concentrations of DMGF for 48 h. Cell viability was measured by MTT assay. Results are shown as mean ± SD ( n = 6). ( B , C ) DMGF increased active caspase-3 activity and TUNEL signals. Paclitaxel (30 ng/mL) was used as a positive control. Ctrl: control (untreated) cells. P: Paclitaxel 30 ng/mL. D1 and D2: DMGF 1 and 2 µg/mL. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared to the control group using one-way ANOVA followed by Dunnett’s multiple comparison test. ( D ) The top 10 differentially down-regulated hallmark pathways in Daoy-MYCN cells after DMGF treatment. ( E ) The genes that overlap with the genes in the hallmark gene sets of MYC target v1, MYC target v2, and G2M checkpoint in Daoy-MYCN cells after DMGF treatment. ( F ) DMGF suppressed MYCN and MYBL2 expression in MB cells. MB cells were treated with DMGF for 48 h; MYCN and MYBL2 were detected by western blot. ( G ) Cell cycle distribution of DMGF-treated MB cells. After treatment for 24 h with DMGF (0 and 2 µg/mL), a propidium iodide staining assay was performed on MB cells. Cell cycle distribution was detected by flow cytometry. All data are represented as mean ± S.D. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared to the control group using one-way ANOVA followed by Dunnett’s multiple comparison test. ( H ) Effect of DMGF on expression of cell cycle checkpoint proteins, such as cyclins, CDKs, p21 and p27. All cell cycle checkpoint proteins were analyzed by Western blot. β-actin was used as a loading control

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Expressing, MTT Assay, Activity Assay, TUNEL Assay, Positive Control, Control, Comparison, Western Blot, Staining, Flow Cytometry

    Therapeutic effects of DMGF alone or in combination with cisplatin on tumor growth in orthotopic MYCN-overexpressing MB mice. SCID mice were inoculated with Daoy-MYCN cells in the left cerebral hemisphere and then intravenously treated with 10 mg/kg DMGF and/or 3 mg/kg cisplatin ( n = 7 for each treatment group and n = 8 for the control group). ( A ) IVIS image of tumor volumes in DMGF and/or cisplatin treated mice. Tumor cells in the C7, C8, and Cis3 mice metastasized to the lung. ( B ) Record of body weights in DMGF and/or cisplatin treated mice. Data are presented as mean ± SD. **, P < 0.01, compared to the untreated group using two-way ANOVA followed by Dunnett’s multiple comparison test. ( C ) Tumor metastasis in DMGF and/or cisplatin treated mice are summarized. Pink: tumor within brain. Blue: tumor metastasized to spine and outside the CNS. ( D ) Record of tumor volumes in DMGF and/or cisplatin-treated mice. Mouse tumor volumes on day 33 were shown ( n = 3–6). Statistical analyses were performed using two-way ANOVA followed by Dunnett’s multiple comparison test. ( E ) Survival curve of DMGF and/or cisplatin treated mice. Statistical analyses were performed using one-way ANOVA with log-rank test for survival curves. ( F ) MYCN, MYBL2 and active caspase-3 expression in tumors from DMGF/cisplatin-treated orthotopic Daoy-MYCN tumor mice. ( G ) M1 and M2 macrophages and their cytokines in tumor from DMGF and/or cisplatin-treated mice

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: Therapeutic effects of DMGF alone or in combination with cisplatin on tumor growth in orthotopic MYCN-overexpressing MB mice. SCID mice were inoculated with Daoy-MYCN cells in the left cerebral hemisphere and then intravenously treated with 10 mg/kg DMGF and/or 3 mg/kg cisplatin ( n = 7 for each treatment group and n = 8 for the control group). ( A ) IVIS image of tumor volumes in DMGF and/or cisplatin treated mice. Tumor cells in the C7, C8, and Cis3 mice metastasized to the lung. ( B ) Record of body weights in DMGF and/or cisplatin treated mice. Data are presented as mean ± SD. **, P < 0.01, compared to the untreated group using two-way ANOVA followed by Dunnett’s multiple comparison test. ( C ) Tumor metastasis in DMGF and/or cisplatin treated mice are summarized. Pink: tumor within brain. Blue: tumor metastasized to spine and outside the CNS. ( D ) Record of tumor volumes in DMGF and/or cisplatin-treated mice. Mouse tumor volumes on day 33 were shown ( n = 3–6). Statistical analyses were performed using two-way ANOVA followed by Dunnett’s multiple comparison test. ( E ) Survival curve of DMGF and/or cisplatin treated mice. Statistical analyses were performed using one-way ANOVA with log-rank test for survival curves. ( F ) MYCN, MYBL2 and active caspase-3 expression in tumors from DMGF/cisplatin-treated orthotopic Daoy-MYCN tumor mice. ( G ) M1 and M2 macrophages and their cytokines in tumor from DMGF and/or cisplatin-treated mice

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Control, Comparison, Expressing

    Brain-wide distribution of MYCN and MYBL2 expression in orthotopic xenograft mice. ( A-C ) Image profiles of the MYCN expression of Daoy-MYCN tumors in orthotopic xenograft mice that did not receive DMGF treatment and ( D-E ) in the DMGF-treated mice. ( A ) IVIS images of Daoy-MYCN tumors were detected on days 3 and 17 in the control mice. ( B ) MYCN expression in different horizontal sections of Daoy-MYCN tumors in the control mice. MYCN is highly expressed in the brain, including the cerebral cortex, hippocampal formations, midbrain, and cerebellum. ( C ) MYCN expression in the spinal cord in orthotopic xenograft mice that did not receive DMGF treatment. ( D ) IVIS images of Daoy-MYCN tumors were detected on days 3 and 17 in the DMGF-treated mice. ( E ) MYCN expression was low in horizontal sections of Daoy-MYCN tumors from mice treated with DMGF. ( F-H ) Image profiles of the MYBL2 expression of Daoy-MYCN tumors in orthotopic xenograft mice that did not receive DMGF treatment and ( I-J ) in the DMGF-treated mice. ( F ) IVIS images of Daoy-MYCN tumors were detected on days 3 and 17 in the control mice. ( G ) MYBL2 expression in different horizontal sections of Daoy-MYCN tumors in the control mice. MYBL2 is highly expressed in the brain, including the cerebral cortex, midbrain, and cerebellum. ( H ) MYBL2 expression in the spinal cord in orthotopic xenograft mice that did not receive DMGF treatment. ( I ) IVIS images of Daoy-MYCN tumors detected at days 3 and 17 in the DMGF-treated mice. ( J ) MYBL2 expression was low in horizontal sections of Daoy-MYCN tumors from mice treated with DMGF. Red: tumor cells with MYCN or MYBL2 expression. 1 and 2 mean Zoom in position 1 and 2 in each section

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: Brain-wide distribution of MYCN and MYBL2 expression in orthotopic xenograft mice. ( A-C ) Image profiles of the MYCN expression of Daoy-MYCN tumors in orthotopic xenograft mice that did not receive DMGF treatment and ( D-E ) in the DMGF-treated mice. ( A ) IVIS images of Daoy-MYCN tumors were detected on days 3 and 17 in the control mice. ( B ) MYCN expression in different horizontal sections of Daoy-MYCN tumors in the control mice. MYCN is highly expressed in the brain, including the cerebral cortex, hippocampal formations, midbrain, and cerebellum. ( C ) MYCN expression in the spinal cord in orthotopic xenograft mice that did not receive DMGF treatment. ( D ) IVIS images of Daoy-MYCN tumors were detected on days 3 and 17 in the DMGF-treated mice. ( E ) MYCN expression was low in horizontal sections of Daoy-MYCN tumors from mice treated with DMGF. ( F-H ) Image profiles of the MYBL2 expression of Daoy-MYCN tumors in orthotopic xenograft mice that did not receive DMGF treatment and ( I-J ) in the DMGF-treated mice. ( F ) IVIS images of Daoy-MYCN tumors were detected on days 3 and 17 in the control mice. ( G ) MYBL2 expression in different horizontal sections of Daoy-MYCN tumors in the control mice. MYBL2 is highly expressed in the brain, including the cerebral cortex, midbrain, and cerebellum. ( H ) MYBL2 expression in the spinal cord in orthotopic xenograft mice that did not receive DMGF treatment. ( I ) IVIS images of Daoy-MYCN tumors detected at days 3 and 17 in the DMGF-treated mice. ( J ) MYBL2 expression was low in horizontal sections of Daoy-MYCN tumors from mice treated with DMGF. Red: tumor cells with MYCN or MYBL2 expression. 1 and 2 mean Zoom in position 1 and 2 in each section

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Expressing, Control

    DMGF effectively induced cell death by inhibiting the expression of MYCN and MYBL2 in primary SHH MB cells. ( A ) Expression of MYCN and MYBL2 in primary cells generated from SHH MB patients in the TVGH/TMUH cohort. ( B , C ) Effects of DMGF on cytotoxicity and anti-migration in primary SHH MB cells. ( D ) DMGF suppressed MYCN and MYBL2 expression in primary SHH MB cells. ***, P < 0.001; ****, P < 0.0001, compared to the untreated group using one-way ANOVA followed by Dunnett’s multiple comparison test. All data are represented as mean ± SD from three independent experiments, each performed in triplicate ( n = 3)

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: DMGF effectively induced cell death by inhibiting the expression of MYCN and MYBL2 in primary SHH MB cells. ( A ) Expression of MYCN and MYBL2 in primary cells generated from SHH MB patients in the TVGH/TMUH cohort. ( B , C ) Effects of DMGF on cytotoxicity and anti-migration in primary SHH MB cells. ( D ) DMGF suppressed MYCN and MYBL2 expression in primary SHH MB cells. ***, P < 0.001; ****, P < 0.0001, compared to the untreated group using one-way ANOVA followed by Dunnett’s multiple comparison test. All data are represented as mean ± SD from three independent experiments, each performed in triplicate ( n = 3)

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Expressing, Generated, Migration, Comparison

    DMGF inhibited MYCN and MYBL2 by interacting activin receptor type IIB (ActRIIB). ( A ) The distinct classes of potential targets of DMGF. The protein targets were predicted by the Way2Drug webtool ( https://www.way2drug.com/passtargets/ ). ( B , C ) ActRIIB expression in MB patient’s tumors and MB cell lines was confirmed. ( D ) Docking of DMGF (pink) into the kinase domain of ActRIIB (AF- Q13705 -F1-v4). DMGF was located at the hinge loop (blue) containing the ATP binding site and interacted with Thr265, Ala266, Asp275, and Lys325. ( E ) DMGF was located at the activation loop (green) and interacted with Arg200, Thr274, Lys323, Ser324, Lys325, Asp339, and Tyr364. ( F-G ) Protein expression of Smad1/5/8 and PI3K/AKT/mTOR pathways

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: DMGF inhibited MYCN and MYBL2 by interacting activin receptor type IIB (ActRIIB). ( A ) The distinct classes of potential targets of DMGF. The protein targets were predicted by the Way2Drug webtool ( https://www.way2drug.com/passtargets/ ). ( B , C ) ActRIIB expression in MB patient’s tumors and MB cell lines was confirmed. ( D ) Docking of DMGF (pink) into the kinase domain of ActRIIB (AF- Q13705 -F1-v4). DMGF was located at the hinge loop (blue) containing the ATP binding site and interacted with Thr265, Ala266, Asp275, and Lys325. ( E ) DMGF was located at the activation loop (green) and interacted with Arg200, Thr274, Lys323, Ser324, Lys325, Asp339, and Tyr364. ( F-G ) Protein expression of Smad1/5/8 and PI3K/AKT/mTOR pathways

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Expressing, Binding Assay, Activation Assay

    The proposed mechanism of DMGF-induced inhibition of MYCN and MYBL2 contributes to cell death, anti-metastasis, and metabolic alteration in SHH MB cells, and affects macrophage polarization

    Journal: Journal of Translational Medicine

    Article Title: 7,7”-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma

    doi: 10.1186/s12967-026-07809-8

    Figure Lengend Snippet: The proposed mechanism of DMGF-induced inhibition of MYCN and MYBL2 contributes to cell death, anti-metastasis, and metabolic alteration in SHH MB cells, and affects macrophage polarization

    Article Snippet: The expression of MYCN and MYBL2 in tumors was determined by staining with anti-mouse MYCN (1:500, Proteintech, Cat#10159-2-AP, RRID: AB_2266881) and anti-mouse MYBL2 (1:500, Proteintech, Cat#18896-1-AP, RRID: AB_10644283) antibodies.

    Techniques: Inhibition